Company Overview and News
2018-10-12 investorplace - 1
It has been more than a week since General Electric (NYSE:GE) announced that it had replaced its now-former CEO, John Flannery. GE stock surged nearly 20% in the wake of the announcement before retreating with the rest of the market The dust has yet to fully settle, though, as investors continue weighing the upside of a highly-motivated, new CEO against the plausible reality that fixing GE still won’t be quick, easy or pretty.
BHI GE GEC AAPL BHGE GNE DHR
Dril-Quip (NYSE:DRQ) has been range-bound for the past several months and I expect the trend to continue with a bias to the upside going into the earnings call on Oct. 26. Specifically, there are two plays with a slightly bullish bias in DRQ stock that I want to share with you, as each play could lead to impressive profits.
DRQ BHI SPN NOV BHGE
2018-10-09 247wallst - 1
Stocks were looking to open lower on Tuesday after a mixed bag with the Dow Jones industrials rising and S&P 500 and Nasdaq falling on Monday. U.S. equity indexes are still quite close to all-time highs despite the rapid rise in long-term interest rates over the past two weeks. One trend that cannot be ignored is that investors have seen lower upside from buying on market pullbacks than in prior years.
DB RCUS WMT CISN BLKB HOVVB HIG AAPL BOX BRPIF CSX HGH MS HOV LNT HOVNP BHGE BHI INTU DOOO DNKN TRI
2018-10-09 zacks - 2
Subsidiaries of General Electric Company (GE - Free Report) has communicated that those are planning to reshape business portfolios. GE Capital has agreed to sell roughly $1 billion worth of equity investments of its Energy Financial Services business while Baker Hughes, a GE company (BHGE - Free Report) has agreed on purchasing 5% stake in a subsidiary of Abu Dhabi National Oil Company. We believe that the aforementioned news will play a vital role in building positive sentiments for General Electric.
BHI GEC GE MIC BHGE GNE APO
When a company struggles the way General Electric Co. (NYSE: GE) has over the past couple of years, the moves a company makes may seem contradictory. Two Monday morning announcements involving GE may make it seem like the right hand does not know what the left hand is doing.
BHI GE GEC BHGE GNE APO
2018-10-08 247wallst - 1
Stocks were looking to open lower on Monday, but it was expected to be a fairly quiet day with the Columbus Day holiday keeping part of the banking system closed. U.S. equity indexes are just under all-time highs, but investors have been seeing lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to position their investments for the rest of 2018 and into 2019.
HAL FB ABT WMT HUN AAPL CAG TMHC ABT SLB EA GE GEC VOD VOD CBT BHGE KMB PBR MDT BHI BLK VODPF TRI GNE SCL SLB
Average Annual Total Returns (09/30/18) Since Inception (11/01/95) 10.08% 10–year 7.51% 5–year 6.99% 1–year 5.29% 3–month 2.46% Gross Expense Ratio as of 09/30/17 was 0.87% Net Expense Ratio as of 09/30/17 was 0.78%
FLEX NOV CVS NKE HCA DOV STT BAC PDCE BHGE ARNC BWA WFCNP PM DOV.WI TEL BAC CHTR LEA GM ORCL WFC MA BHI OCLCF UNH
Baker Hughes, a GE company (BHGE - Free Report) intends to bid for a production sharing contract likely to be tendered by Petroleo Brasileiro S.A. (PBR - Free Report) or Petrobras SA, per Reuters. Notably, this is the first time that Petrobras will be inviting bids for production sharing accord from oilfield services players.
BHI HD OMP SHLX BHGE
HOUSTON & LONDON--(BUSINESS WIRE)--Oct. 5, 2018-- Baker Hughes, a GE company (NYSE:BHGE) announced today that the Baker Hughes international rig count for September 2018 was 1,004, down 4 from the 1,008 counted in August 2018, and up 73 from the 931 counted in September 2017. The international offshore rig count for September 2018 was 204, down 8 from the 212 counted in August 2018, and up 14 from the 190 counted in September 2017.
NEW DELHI--(BUSINESS WIRE)--Oct. 3, 2018-- Baker Hughes, a GE company (NYSE: BHGE), McDermott International, Inc. (NYSE: MDR) and L&T Hydrocarbon Engineering (LTHE), a subsidiary of Larsen & Toubro (NSE: LT), were awarded the subsea contract for India's Oil & Natural Gas Corporation's (ONGC) largest deepwater project, the development of block DWN-98/2 in the Krishna Godavari basin. The project brings together leading subsea equipment and services from BHGE, McDermott and LTHE to provide ONGC with end-to-end project delivery.
BHI BHGE MDR LT MCDFF
As recently as January 2017, General Electric (NYSE:GE) traded for more than $30 per share. It has subsequently lost almost two-thirds of its value. The last time GE stock collapsed this badly was during the worldwide financial crisis. GE, which at the time owned a major finance business, was understandably affected by the crisis.
BRK.A BHI GE GEC TWTR BHGE GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET